

# Genitourinary Committee

## Leadership

Chair: ..... Ian M. Thompson, Jr., MD  
Vice-Chair: ..... Daniel P. Petrylak, MD  
Executive Officer: ..... Christopher W. Ryan, MD  
Statisticians: ..... Cathy M. Tangen, DrPH  
..... Melissa Plets, MS  
..... Eddie Mayerson, MS

## Scientific Leadership

Translational Medicine: ..... David J. McConkey, PhD (GU Chair)  
..... Joshua J. Meeks, MD, PhD (Bladder)  
..... Amir Goldkorn, MD (Prostate)  
..... Sumanta "Monty" K. Pal, MD (Renal)  
Radiation Oncology: ..... James B. Yu, MD  
..... Daniel A. Hamstra, MD  
Imaging: ..... Evan Y. Yu, MD  
..... Hiram Shaish, MD  
..... John D. Hazle, PhD  
Pathology: ..... M. Scott Lucia, MD  
Surgery: ..... Kelly L. Stratton, MD  
Liaison to the SPORES: ..... Colin P.N. Dinney, MD  
Early Therapeutics: ..... Neeraj Agarwal, MD  
Bladder Organ Site Chairs: ..... Seth P. Lerner, MD (Localized)  
..... Thomas W. Flaig, MD (Localized)  
..... Daniel P. Petrylak, MD (Advanced)  
Prostate Organ Site Chairs: ..... Daniel W. Lin, MD (Localized)  
..... David I. Quinn, MD, PhD (Advanced)  
Renal Organ Site Chairs: ..... Brian Shuch, MD (Localized)  
..... Ulka N. Vaishampayan, MD (Advanced)

## Designates

Cancer Control: ..... Peter J. Van Veldhuizen, Jr., MD  
Digital Engagement: ..... Neema Navai, MD  
Veterans Affairs: ..... Michael M. Goodman, MD  
Data Coordinators: ..... Jeri Jardine  
..... Tonya Johnson  
..... Michele Counts  
..... Laura Wells  
Oncology Research Professionals:  
CRAs: ..... Abigail L. Cornette, MS  
..... Cheryl Farlow, RN, OCN  
Nurses: ..... Deborah A. Shaw, RN  
..... Cheryl Kefauver, RN  
Patient Advocates: ..... Rick Bangs, MBA (Bladder)  
..... Tony Crispino (Prostate)

..... Margaret "Peggy" Zuckerman, MEd (Renal)  
Pharmaceutical Science: ..... Joyce Lee, PharmD  
..... Allison Schepers, PharmD  
Protocol Project Manager: ..... Taj Pereira  
Clinical Trials Program Manager: ..... TBD

## Time/Location

GU Committee Part I: Friday, April 8, 2022 3:15 - 6:15 pm  
Room: Columbia CD, Level 3

## Time/Location

GU Committee Part II: Saturday, April 9, 2022 8:30 - 11:30 am  
Room: Columbia CD, Level 3

## Agenda

### GU Committee Part I

3:15 – 3:30 – Chair's Welcome and Opening Remarks. Ian Thompson  
3:30 – 4:45 – Renal Organ site. (Dr Ulka Vaishampayan and Dr. Brian Shuch)  
4:45 – 5:55 – Translational Medicine (Dr. David McConkey)  
5:55 – 6:15 – Cancer Control (Dr Peter Van Veldhuizen)

### Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

## Priority Study

**S1931**, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Ne-phrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

## Concepts in Development

**S2200**, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)" Drs. B. Maughan and S. Pal. Initial protocol submission to CTEP: 1/21/22.

## Active Studies

**CTS/AAREN1721**, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

# Genitourinary Committee

**CTSU/A031704**, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

**CTSU/A031801**, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

**CTSU/A031901**, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

## Closed Studies

**S1500**, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

**S0931**, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

**CTSU/E2810**, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

**CTSU/A031501**, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

**CTSU/EA8143**, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

## Translational Medicine

Chair: Dr. David McConkey

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

## Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

## Active Studies

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

## Diverse Studies of Interest

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

**CTSU/A031702**, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, E, F, G, I.

**CTSU/EAY 131**, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subproto-cols A, C1, C2, E, L, V, Z1E, and Z1 are closed to accrual: 1/31/22.

**CTSU/EA8134**, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

## Agenda

### GU Committee Part II

8:30-9:45 – Bladder Organ Site (Drs Seth Lerner and Thomas Flaig)

9:45-11:30 – Prostate Organ Site (Drs. Tanya Dorff and Daniel Lin)

### Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Seth Lerner (Local).

### Priority Study

**S2011**, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde M. Liss, and S. Lerner, et al. Activated: 10/6/21.

# Genitourinary Committee

## Active Studies

**S1937**, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21.

**S1806**, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19.

**CTSU/A031701**, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

**CTSU/A031803**, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

**CTSU/EA8185**, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

## Closed Studies

**S1011**, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

**S1602**, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

**S1605**, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

## Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

## Priority Study

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or

Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

## Concepts in Development

**S2210**, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Concept submission to CTEP: 2/8/22.

## Active Studies

**CTSU/A031102**, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Re-lapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

**CTSU/EA8171**, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

**CTSU/NRG-GU002**, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

**CTSU/NRG-GU005**, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17.

**CTSU/AGCT1531**, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

## Closed Studies

**S1216**, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

**CTSU/NRG-GU006**, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

**CTSU/NRG-GU009**, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk

# Genitourinary Committee

and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT\*).” Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

**CTSU/RTOG-0924**, “Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

**CTSU/NRG-GU007**, “Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR\*) \*Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I).” Dr. D. VanderWeele. Acti- vated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1

additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21.

**CTSU/NRG-GU008**, “Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE\*) \*Intensifying Treatment for Node Positive Prostate

Cancer by Varying the Hormonal Therapy.” Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21


**CTSU/EA8153**, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

## Get the Scoop!

Want the Front Line blog every Friday?

Or the Translational Medicine Link of the Week?

How about the Hope Foundation Monthly E-Newsletter?



*Email communications@swog.org to get on a list – one or all three*

## Genitourinary Committee

### Accrual from trial opening through 12/31/2021 by Institution and Study

	S1602	S1802	S1806	S1931	S1937	A031102	A031501	A031701	A031702	A031704	A031801	A031803	A031902	EA8134	EA8143
Ascension Prov Hospitals - Southfield	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-
Banner MD Anderson CC	7	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	6	-	1	-	-	-	-	-	-	-	-	-	-	7
Baylor Coll Med/Dan L Duncan CCC	21	1	2	-	-	-	1	-	-	-	-	-	-	-	1
CWRU Case CCC LAPS	-	-	-	-	-	-	-	4	-	-	-	-	2	-	-
Ca Res Consortium West Mich NCORP	-	2	2	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	10	1	1	-	-	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	12	-	5	1	-	-	-	-	-	-	-	-	-	-	8
City of Hope CCC	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	1	-	-	-	3	-	-	-	-	-	-	-	1
CommonSpirit Health Research Inst	-	-	2	-	1	-	-	-	-	-	-	-	-	-	4
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-
Dayton NCORP	1	3	-	-	-	-	-	-	-	1	-	-	-	-	1
Fred Hutchinson Ca Res Ctr LAPS	26	8	-	-	-	-	-	-	-	-	-	-	-	-	4
Georgia Cares MU NCORP	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
Gulf South MU NCORP	95	60	40	-	-	-	2	-	-	-	1	9	-	-	10
Hawaii MU NCORP	9	-	2	-	-	-	-	-	-	-	-	-	-	-	2
Heartland Ca Res NCORP	4	8	3	-	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	13	16	3	-	-	-	1	-	1	5	-	-	-	-	3
Houston Methodist Hospital	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	12	14	-	-	-	-	14	-	-	40	-	-	-	-	41
Lahey Hospital & Med Ctr	-	-	-	-	-	-	4	-	6	-	-	-	-	-	4
Loma Linda U Med Ctr	-	-	-	-	-	-	2	-	-	-	-	-	-	-	-
Loyola U Med Ctr	12	9	4	-	-	-	-	-	1	1	-	-	-	-	4
Massachusetts Veterans ERIC	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-
Medical U South Carolina MU NCORP	2	2	-	-	-	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consortium NCORP	6	7	9	-	1	-	-	-	-	-	-	-	-	-	-
Moffitt CC	26	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Montana Cancer Consortium NCORP	1	3	-	-	-	-	-	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	1	6	-	-	-	-	-	-	-	1	-	-	-	-	1
Nevada Ca Res Foundation NCORP	2	1	-	-	-	-	-	-	-	-	-	-	-	-	2
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	-	-	-	-	1	-	-	-	-	-
Northwestern U LAPS	35	-	6	-	-	-	-	-	-	1	-	-	-	-	-
Ohio State U CCC LAPS	4	1	1	-	-	-	-	-	-	-	-	-	-	-	-



## Genitourinary Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1602	S1802	S1806	S1931	S1937	A031102	A031501	A031701	A031702	A031704	A031801	A031803	A031902	EA8134	EA8143
Oregon Health & Science U	14	-	1	-	-	-	-	-	3	3	-	-	-	-	14
Pacific Ca Res Consortium NCORP	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consortium	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-
Tulane U Health Sciences Ctr	-	-	-	4	-	-	-	-	-	-	-	-	-	-	10
UC Davis CCC LAPS	-	9	7	-	-	-	4	4	-	2	2	3	-	-	1
UC Irvine Health/Chao Family CCC	16	2	3	-	-	-	-	-	-	-	-	-	-	-	1
UC San Diego Moores CC	-	1	1	-	-	-	-	-	-	-	-	-	-	-	2
UCLA / Jonsson CCC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8
USC Norris CCC LAPS	44	5	-	-	2	11	13	-	3	-	-	-	-	8	-
U Alabama Birm/Deep South RC LAPS	-	-	-	-	-	-	-	-	1	-	1	1	-	-	6
U Arkansas for Medical Sciences	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	4	3	1	-	-	-	-	-	6	-	-	-	-	-
U Colorado CC LAPS	23	4	2	-	-	-	13	-	-	7	-	-	-	-	1
U Kansas CC - MCA Rural MU NCORP	20	7	4	-	-	-	5	-	1	4	-	-	-	-	2
U Kentucky/Markey CC	-	-	2	-	-	-	-	-	-	-	-	-	-	-	12
U Michigan CCC LAPS	30	2	-	5	-	-	18	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	-	1	-	-	-	-	-	-	1	-	-	-	-	-	3
U Oklahoma Health Sciences Ctr LAPS	51	25	14	2	-	-	-	-	-	-	-	-	-	-	-
U Rochester LAPS	20	17	-	-	-	-	-	-	3	5	-	-	-	-	1
U Texas HSC at San Antonio	58	2	-	1	-	-	-	-	-	-	-	4	-	-	14
U Texas MD Anderson CC LAPS	38	61	-	-	-	-	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	47	15	-	1	-	-	3	-	-	-	-	-	-	-	2
Upstate Carolina Consortium NCORP	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	1	-	-	-	-	-	-	-	-	-	-	-	-	2
Western States Ca Res NCORP	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	4	3	-	-	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	3	1	1	-	-	-	8	-	-	-	-	-	-	-	1
ALLIANCE	110	72	12	-	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	111	51	22	-	-	-	-	-	-	-	-	-	-	-	-
NRG	88	54	68	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>1,000</b>	<b>497</b>	<b>233</b>	<b>16</b>	<b>4</b>	<b>11</b>	<b>93</b>	<b>8</b>	<b>20</b>	<b>78</b>	<b>4</b>	<b>17</b>	<b>3</b>	<b>8</b>	<b>174</b>

## Genitourinary Committee

### Accrual from trial opening through 12/31/2021 by Institution and Study

	EA8153	EA8171	EA8183	EA8191	NRGGU002	NRGGU005	NRGGU008	NRGGY023
Ascension Prov Hospitals - Southfield	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	-	-	-	-	-	-	-
Baylor Coll Med/Dan L Duncan CCC	-	-	-	-	-	-	-	-
CWRU Case CCC LAPS	-	-	-	-	-	-	-	-
Ca Res Consortium West Mich NCORP	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	-	-	-	-	-	-
Ca Res of Wisconsin & N Mich Consort	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	-	-	-	-	-	-	-
City of Hope CCC	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Inst	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-
Gulf South MU NCORP	-	11	-	-	1	1	3	-
Hawaii MU NCORP	-	1	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	10	-	-	-	-	-	-	-
Lahey Hospital & Med Ctr	-	-	1	-	-	-	-	-
Loma Linda U Med Ctr	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	-	-	-	-	-	-	-
Massachusetts Veterans ERIC	-	-	-	-	-	-	-	-
Medical U South Carolina MU NCORP	-	-	-	-	-	-	-	-
Michigan Ca Res Consortium NCORP	-	-	-	-	-	-	-	-
Moffitt CC	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	-	-	-	-	-	-	-
Nevada Ca Res Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico MU NCORP	-	-	-	-	-	1	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-
Ohio State U CCC LAPS	-	-	-	-	-	-	-	-

## Genitourinary Committee

**Accrual from trial opening through 12/31/2021 by Institution and Study**

	EA8153	EA8171	EA8183	EA8191	NRGGU002	NRGGU005	NRGGU008	NRGGY023
Oregon Health & Science U	-	2	-	-	-	-	-	-
Pacific Ca Res Consortium NCORP	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-
Sutter Ca Res Consortium	-	-	-	-	-	2	-	1
Tulane U Health Sciences Ctr	-	-	-	-	-	1	-	-
UC Davis CCC LAPS	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family CCC	-	-	-	-	-	-	-	-
UC San Diego Moores CC	-	-	-	-	-	-	-	-
UCLA / Jonsson CCC	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	-	-	-	-	-	-	-	-
U Alabama Birm/Deep South RC LAPS	-	-	-	-	-	-	-	-
U Arkansas for Medical Sciences	-	-	-	-	-	-	-	-
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-
U Colorado CC LAPS	-	-	-	-	1	1	-	-
U Kansas CC - MCA Rural MU NCORP	1	-	-	-	-	-	-	-
U Kentucky/Markey CC	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	2	-	-	-	1	-	-	-
U Oklahoma Health Sciences Ctr LAPS	-	-	-	1	-	-	-	-
U Rochester LAPS	-	-	-	-	-	-	-	-
U Texas HSC at San Antonio	-	45	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	8	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	8	-	-	-	-	-	-	-
Upstate Carolina Consortium NCORP	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram CC LAPS	-	-	-	-	-	-	-	-
Virginia Mason Med Ctr	-	-	-	-	-	3	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	1	-	-	-
Western States Ca Res NCORP	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	2	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
<b>Total</b>	<b>31</b>	<b>59</b>	<b>1</b>	<b>1</b>	<b>4</b>	<b>9</b>	<b>3</b>	<b>1</b>